Safety and Acceptance of COVID-19 Vaccination After Multisystem Inflammatory Syndrome in Children (MIS-C) in Spain
Open Access
- 29 July 2022
- journal article
- letter
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 11 (10) , 471-473
Abstract
In this cohort of 42 adolescents with a previous multisystem inflammatory syndrome (MIS-C) diagnosis, 32 (76.2%) were vaccinated with COVID-19 vaccines, with a low incidence of relevant adverse events. More importantly, no new MIS-C or myocarditis occurred after a median of 10 weeks (range 5.3-19.7) post-vaccination.Keywords
Funding Information
- Instituto de Salud Carlos III
- European Regional Development Fund
- Servicio Madrileño de Salud-Fundación para la Investigación Biomédica del Hospital 12 de Octubre (PI20/00095)
- Spanish Ministry of Science and Innovation
- Instituto de Salud Carlos III
- Fondos Europeos de Desarrollo Regional (CM19/00015)
- Asociación Española de Pediatría (COVID-19 EPICO-AEP 2020)
This publication has 2 references indexed in Scilit:
- Clinical spectrum of COVID-19 and risk factors associated with severity in Spanish childrenEuropean Journal of Pediatrics, 2021
- COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021MMWR. Morbidity and Mortality Weekly Report, 2021